Tweet
Bank of New York Mellon Corp trimmed its holdings in shares of Celgene Co. (NASDAQ:CELG) by 6.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,533,915 shares of the biopharmaceutical company's stock after selling 487,641 shares during the period. Bank of New York Mellon Corp owned about 0.93% of Celgene worth $518,923,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also modified their holdings of the company. Old Mutual Global Investors UK Ltd. boosted its holdings in shares of Celgene by 4,047.3% in the 1st quarter. Old Mutual Global Investors UK Ltd. now owns 1,576,831 shares of the biopharmaceutical company's stock valued at $140,669,000 after buying an additional 1,538,810 shares in the last quarter. Natixis boosted its holdings in shares of Celgene by 245.6% in the 1st quarter. Natixis now owns 1,746,416 shares of the biopharmaceutical company's stock valued at $155,798,000 after buying an additional 1,241,120 shares in the last quarter. Swedbank boosted its holdings in shares of Celgene by 25.0% in the 2nd quarter. Swedbank now owns 3,881,075 shares of the biopharmaceutical company's stock valued at $308,235,000 after buying an additional 777,099 shares in the last quarter. Chevy Chase Trust Holdings Inc. bought a new stake in shares of Celgene in the 2nd quarter valued at about $51,914,000. Finally, Redmile Group LLC bought a new stake in shares of Celgene in the 4th quarter valued at about $68,147,000. Institutional investors own 76.82% of the company's stock. Get Celgene alerts:
In other Celgene news, Director John H. Weiland purchased 5,575 shares of Celgene stock in a transaction on Tuesday, August 7th. The stock was bought at an average cost of $89.73 per share, with a total value of $500,244.75. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink . Also, Director Ernest Mario sold 12,000 shares of the firm's stock in a transaction that occurred on Thursday, August 9th. The stock was sold at an average price of $92.32, for a total transaction of $1,107,840.00. Following the transaction, the director now directly owns 44,413 shares of the company's stock, valued at $4,100,208.16. The disclosure for this sale can be found here . Insiders have sold a total of 42,750 shares of company stock valued at $3,533,390 over the last three months. 0.39% of the stock is currently owned by insiders. CELG opened at $90.15 on Friday. Celgene Co. has a 12-month low of $74.13 and a 12-month high of $147.17. The company has a quick ratio of 1.40, a current ratio of 1.52 and a debt-to-equity ratio of 5.76. The company has a market cap of $64.15 billion, a price-to-earnings ratio of 13.18, a price-to-earnings-growth ratio of 0.57 and a beta of 1.32.
Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, July 26th. The biopharmaceutical company reported $2.16 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.11 by $0.05. Celgene had a net margin of 19.81% and a return on equity of 87.28%. The company had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.70 billion. During the same period last year, the firm posted $1.82 EPS. Celgene's revenue for the quarter was up 16.6% compared to the same quarter last year. analysts expect that Celgene Co. will post 7.64 EPS for the current year.
Celgene declared that its board has initiated a share repurchase program on Thursday, May 24th that allows the company to buyback $3.00 billion in shares. This buyback authorization allows the biopharmaceutical company to purchase up to 5.4% of its shares through open market purchases. Shares buyback programs are often a sign that the company's management believes its stock is undervalued.
A number of research firms have recently weighed in on CELG. BidaskClub upgraded shares of Celgene from a "hold" rating to a "buy" rating in a report on Thursday. Zacks Investment Research upgraded shares of Celgene from a "sell" rating to a "strong-buy" rating and set a $102.00 price target on the stock in a report on Wednesday, August 1st. Mizuho reaffirmed a "buy" rating and issued a $129.00 price objective on shares of Celgene in a research report on Tuesday, July 31st. SunTrust Banks reaffirmed a "hold" rating and issued a $101.00 price objective on shares of Celgene in a research report on Friday, July 27th. Finally, Morgan Stanley increased their price objective on shares of Celgene from $91.00 to $93.00 and gave the company an "equal weight" rating in a research report on Friday, July 27th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, twenty-one have issued a buy rating and two have given a strong buy rating to the stock. The stock has an average rating of "Buy" and a consensus target price of $121.85.
Celgene Profile
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Read More: Average Daily Trade Volume â€“ ADTV
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG). Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter 